FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948966189> ?p ?o ?g. }

• W2948966189 endingPage "e1002813" @default.
• W2948966189 startingPage "e1002813" @default.
• W2948966189 abstract "Magnetic resonance imaging (MRI) combined with targeted biopsy (TB) is increasingly used in men with clinically suspected prostate cancer (PCa), but the long acquisition times, high costs, and inter-center/reader variability of routine multiparametric prostate MRI limit its wider adoption.The aim was to validate a previously developed unique MRI acquisition and reporting protocol, IMPROD biparametric MRI (bpMRI) (NCT01864135), in men with a clinical suspicion of PCa in a multi-institutional trial (NCT02241122). IMPROD bpMRI has average acquisition time of 15 minutes (no endorectal coil, no intravenous contrast use) and consists of T2-weighted imaging and 3 separate diffusion-weighed imaging acquisitions. Between February 1, 2015, and March 31, 2017, 364 men with a clinical suspicion of PCa were enrolled at 4 institutions in Finland. Men with an equivocal to high suspicion (IMPROD bpMRI Likert score 3-5) of PCa had 2 TBs of up to 2 lesions followed by a systematic biopsy (SB). Men with a low to very low suspicion (IMPROD bpMRI Likert score 1-2) had only SB. All data and protocols are freely available. The primary outcome of the trial was diagnostic accuracy-including overall accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value-of IMPROD bpMRI for clinically significant PCa (SPCa), which was defined as a Gleason score ≥ 3 + 4 (Gleason grade group 2 or higher). In total, 338 (338/364, 93%) prospectively enrolled men completed the trial. The accuracy and NPV of IMPROD bpMRI for SPCa were 70% (113/161) and 95% (71/75) (95% CI 87%-98%), respectively. Restricting the biopsy to men with equivocal to highly suspicious IMPROD bpMRI findings would have resulted in a 22% (75/338) reduction in the number of men undergoing biopsy while missing 4 (3%, 4/146) men with SPCa. The main limitation is uncertainty about the true PCa prevalence in the study cohort, since some of the men may have PCa despite having negative biopsy findings.IMPROD bpMRI demonstrated a high NPV for SPCa in men with a clinical suspicion of PCa in this prospective multi-institutional clinical trial.ClinicalTrials.gov NCT02241122." @default.
• W2948966189 created "2019-06-14" @default.
• W2948966189 creator A5009398971 @default.
• W2948966189 creator A5019493297 @default.
• W2948966189 creator A5021480179 @default.
• W2948966189 creator A5028872145 @default.
• W2948966189 creator A5032369223 @default.
• W2948966189 creator A5037736487 @default.
• W2948966189 creator A5037739817 @default.
• W2948966189 creator A5038379862 @default.
• W2948966189 creator A5040800642 @default.
• W2948966189 creator A5043984769 @default.
• W2948966189 creator A5045990268 @default.
• W2948966189 creator A5046931565 @default.
• W2948966189 creator A5047560906 @default.
• W2948966189 creator A5050153046 @default.
• W2948966189 creator A5055598912 @default.
• W2948966189 creator A5061131802 @default.
• W2948966189 creator A5066264896 @default.
• W2948966189 creator A5079815497 @default.
• W2948966189 creator A5079970260 @default.
• W2948966189 creator A5083097049 @default.
• W2948966189 creator A5089567031 @default.
• W2948966189 creator A5091050704 @default.
• W2948966189 date "2019-06-03" @default.
• W2948966189 modified "2023-10-18" @default.
• W2948966189 title "Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial" @default.
• W2948966189 cites W1590853871 @default.
• W2948966189 cites W1827911007 @default.
• W2948966189 cites W1873854863 @default.
• W2948966189 cites W1917907085 @default.
• W2948966189 cites W1944136062 @default.
• W2948966189 cites W1971348077 @default.
• W2948966189 cites W1978219824 @default.
• W2948966189 cites W2021411036 @default.
• W2948966189 cites W2115726304 @default.
• W2948966189 cites W2122433942 @default.
• W2948966189 cites W2129326192 @default.
• W2948966189 cites W2146373036 @default.
• W2948966189 cites W2165244071 @default.
• W2948966189 cites W2297738055 @default.
• W2948966189 cites W2340422569 @default.
• W2948966189 cites W2514563112 @default.
• W2948966189 cites W2531825705 @default.
• W2948966189 cites W2577453388 @default.
• W2948966189 cites W2587136869 @default.
• W2948966189 cites W2602353650 @default.
• W2948966189 cites W2736990592 @default.
• W2948966189 cites W2772376922 @default.
• W2948966189 cites W2778155315 @default.
• W2948966189 cites W2793874553 @default.
• W2948966189 cites W2793905111 @default.
• W2948966189 cites W2805452553 @default.
• W2948966189 cites W2893199713 @default.
• W2948966189 cites W2900548778 @default.
• W2948966189 cites W2901859788 @default.
• W2948966189 cites W2922071185 @default.
• W2948966189 cites W2980750914 @default.
• W2948966189 doi "https://doi.org/10.1371/journal.pmed.1002813" @default.
• W2948966189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6546206" @default.
• W2948966189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31158230" @default.
• W2948966189 hasPublicationYear "2019" @default.
• W2948966189 type Work @default.
• W2948966189 sameAs 2948966189 @default.
• W2948966189 citedByCount "39" @default.
• W2948966189 countsByYear W29489661892019 @default.
• W2948966189 countsByYear W29489661892020 @default.
• W2948966189 countsByYear W29489661892021 @default.
• W2948966189 countsByYear W29489661892022 @default.
• W2948966189 countsByYear W29489661892023 @default.
• W2948966189 crossrefType "journal-article" @default.
• W2948966189 hasAuthorship W2948966189A5009398971 @default.
• W2948966189 hasAuthorship W2948966189A5019493297 @default.
• W2948966189 hasAuthorship W2948966189A5021480179 @default.
• W2948966189 hasAuthorship W2948966189A5028872145 @default.
• W2948966189 hasAuthorship W2948966189A5032369223 @default.
• W2948966189 hasAuthorship W2948966189A5037736487 @default.
• W2948966189 hasAuthorship W2948966189A5037739817 @default.
• W2948966189 hasAuthorship W2948966189A5038379862 @default.
• W2948966189 hasAuthorship W2948966189A5040800642 @default.
• W2948966189 hasAuthorship W2948966189A5043984769 @default.
• W2948966189 hasAuthorship W2948966189A5045990268 @default.
• W2948966189 hasAuthorship W2948966189A5046931565 @default.
• W2948966189 hasAuthorship W2948966189A5047560906 @default.
• W2948966189 hasAuthorship W2948966189A5050153046 @default.
• W2948966189 hasAuthorship W2948966189A5055598912 @default.
• W2948966189 hasAuthorship W2948966189A5061131802 @default.
• W2948966189 hasAuthorship W2948966189A5066264896 @default.
• W2948966189 hasAuthorship W2948966189A5079815497 @default.
• W2948966189 hasAuthorship W2948966189A5079970260 @default.
• W2948966189 hasAuthorship W2948966189A5083097049 @default.
• W2948966189 hasAuthorship W2948966189A5089567031 @default.
• W2948966189 hasAuthorship W2948966189A5091050704 @default.
• W2948966189 hasBestOaLocation W29489661891 @default.
• W2948966189 hasConcept C121608353 @default.
• W2948966189 hasConcept C126322002 @default.
• W2948966189 hasConcept C126838900 @default.
• W2948966189 hasConcept C143409427 @default.

• next